Flecainide

Flecainide-d4 · Flecaine · Flecanide · FLECAINIDE · rac Flecainide · FLECAINTDE BASE · Flecainide USP/EP/BP · (±)-Flecainide solution

https://huagongshe.com/ko/chemical/3356

식별자 및 물리적 특성

CAS No.	54143-55-4
분자식	C17H20F6N2O3
평균 분자량	414.34 g/mol
단동위원소 질량	414.13781148 g/mol
SMILES	O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F
InChIKey	DJBNUMBKLMJRSA-UHFFFAOYSA-N
PubChem CID	3356
ChEMBL	CHEMBL652
ChEBI	CHEBI:75984
EC No.	685-650-9
DTXSID	DTXSID8023054

화학 및 물리적 성질

XLogP	3.8
극성 표면적	59.6
수소 결합 공여자 수	2
수소 결합 수용자 수	10
회전 가능 결합 수	7
무거운 원자 수	28
형식 전하	0
복잡도	500
LogP(분배 계수)	3.784.6
용해도	48.43.24e-02 g/L클로로포름(약간 용해됨), 메탄올(약간 용해됨)
녹는점	228-229105-1070C
Physical Description	Solid
Dissociation Constants	9.3
Kovats Retention Index	22712211.32230.5
Collision Cross Section	192.2 Å² [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]
끓는 점	434.9±45.0 °C(Predicted)
밀도	1.286±0.06 g/cm3(Predicted)
인화점	9℃
저장 조건	Keep in dark place,Inert atmosphere,Room temperature
물리적 상태	고체
pKa(산도 계수)	pKa 9.3 (Uncertain)
색상	흰색에서 황백색까지
BCS Class	1 or 2
주요 응용	임상 시험
InChI	1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)
InChIKey	DJBNUMBKLMJRSA-UHFFFAOYSA-N
SMILES	O=C(NCC1CCCCN1)C2=CC(OCC(F)(F)F)=CC=C2OCC(F)(F)F
NIST	Benzamide, n-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-(54143-55-4)

화학적 성질

White Crystalline Powder

안전 및 규제

GHS 분류	WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]H336 (50%): May cause drowsiness or dizziness [Warning Specific target organ toxicity, single exposureNarcotic effects]H361 (50%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]H361d (50%): Suspected of damaging the unborn child [Warning Reproductive toxicity]P203, P261, P264, P270, P271, P280, P301+P317, P304+P340, P318, P319, P330, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
규제 정보	Status: Active Update: 10-05-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/24769
Hazard Classes and Categories	Acute Tox. 4 (100%)STOT SE 3 (50%)Repr. 2 (50%)
Treatment	Treatment of flecainide toxicity involves increasing the excretion of flecainide, blocking its effects in the heart, and (rarely) institution of cardiovascular support to avoid impending lethal arrhythmias. Modalities that have had success include administration of a beta-sympathomimetic agent, and administration of a sodium load (often in the form of hypertonic sodium bicarbonate). Placing the individual on cardiopulmonary bypass support may be necessary in order to temporarily obviate the need for a beating heart and to increase blood flow to the liver. (L1129)
건강 영향	Signs of flecainide toxicity include marked prolongation of the PR interval and widening of the QRS duration on the surface ECG. There may be signs and symptoms attributable to overt heart failure secondary to sudden decreased myocardial contractility (L1129).
Hepatotoxicity	In clinical trials, flecainide was associated with a low rate of serum aminotransferase and alkaline phosphatase elevations. Despite wide scale use, flecainide has only rarely been linked to cases of clinically apparent liver injury. The typical presentation is with a cholestatic hepatitis arising within 1 to 6 weeks of starting flecainide. In addition, instances of acute hepatic injury arising within 1 to 3 days of starting flecainide with marked, but short lived elevations in serum aminotransferase levels and minimal increases in alkaline phosphatase have been published, but may actually represent acute worsening of congestive heart failure and ischemic hepatitis due to the proarrhythmic effects of flecainide. In all instances, the liver injury was self limited. Immunoallergic and autoimmune features were not present.

용도

개요

From the chemical point, flecainide is an analog of procainamide, to which a 2.2.2-trifluoroethoxyl group was added at C2 and C3 of the benzene ring, and a diaminoethyl side chain is ended in the piperidine ring.

용도

Flecainide, as with other local anesthetics, is used for naturally occurring ventricular arrhythmia.